Literature DB >> 20006707

Non-viral nanosystems for systemic siRNA delivery.

Stephanie David1, Bruno Pitard, Jean-Pierre Benoît, Catherine Passirani.   

Abstract

To use siRNA (small interfering ribonucleic acids) for systemic administration, a delivery system is often necessary to overcome barriers between administration and the target sites. These delivery systems require different properties to be efficient. On the one hand, they have to protect siRNA from degradation and/or inactivation and, on the other hand, they have themselves to be stable in blood and possess stealth properties to avoid elimination and degradation. Active and/or passive targeting should help the delivery system to reach the desired cell type or tissue, to be internalised, and to deliver siRNA to the cytoplasm so that siRNA can act by RNA interference and inhibit protein synthesis. This review presents an overview of different non-viral delivery systems, which have been evaluated in vivo or entered in clinical trials, with a focus on their physicochemical properties in order to help the development of new and efficient siRNA delivery systems, as the therapeutic solutions of tomorrow. Copyright 2009 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2009        PMID: 20006707     DOI: 10.1016/j.phrs.2009.11.013

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  19 in total

1.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

2.  Nonionic surfactant vesicles for delivery of RNAi therapeutics.

Authors:  Orapan Paecharoenchai; Lesheng Teng; Bryant C Yung; Lirong Teng; Praneet Opanasopit; Robert J Lee
Journal:  Nanomedicine (Lond)       Date:  2013-11       Impact factor: 5.307

3.  Enhanced stability and knockdown efficiency of poly(ethylene glycol)-b-polyphosphoramidate/siRNA micellar nanoparticles by co-condensation with sodium triphosphate.

Authors:  Masataka Nakanishi; Rajesh Patil; Yong Ren; Rishab Shyam; Philip Wong; Hai Quan Mao
Journal:  Pharm Res       Date:  2011-03-09       Impact factor: 4.200

4.  Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy.

Authors:  Robert H Mo; Jennica L Zaro; Wei-Chiang Shen
Journal:  Mol Pharm       Date:  2011-12-28       Impact factor: 4.939

5.  Efficient protection and transfection of small interfering RNA by cationic shell-crosslinked knedel-like nanoparticles.

Authors:  Yuefei Shen; Huafeng Fang; Ke Zhang; Ritu Shrestha; Karen L Wooley; John-Stephen A Taylor
Journal:  Nucleic Acid Ther       Date:  2013-04       Impact factor: 5.486

6.  Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden.

Authors:  James Finlay; Cai M Roberts; Juyao Dong; Jeffrey I Zink; Fuyuhiko Tamanoi; Carlotta A Glackin
Journal:  Nanomedicine       Date:  2015-06-24       Impact factor: 5.307

7.  Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.

Authors:  Khaled Messaoudi; Patrick Saulnier; Kim Boesen; Jean-Pierre Benoit; Frederic Lagarce
Journal:  Int J Nanomedicine       Date:  2014-03-24

8.  Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.

Authors:  Lu Hou; Zheyu Song; Zhonghang Xu; Yuanyu Wu; Wei Shi
Journal:  Int J Nanomedicine       Date:  2020-03-02

9.  Phospholipid-modified polyethylenimine-based nanopreparations for siRNA-mediated gene silencing: implications for transfection and the role of lipid components.

Authors:  Gemma Navarro; Sean Essex; Rupa R Sawant; Swati Biswas; Dattatri Nagesha; Srinivas Sridhar; Conchita Tros de ILarduya; Vladimir P Torchilin
Journal:  Nanomedicine       Date:  2013-08-06       Impact factor: 5.307

10.  Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer's.

Authors:  Natalia Lopez-Barbosa; Juan G Garcia; Javier Cifuentes; Lina M Castro; Felipe Vargas; Carlos Ostos; Gloria P Cardona-Gomez; Alher Mauricio Hernandez; Juan C Cruz
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.